Reuters: Did the Neurontin Lawsuit Fuel Health Spending?
In 2004, Pfizer, the world's largest drug company, agreed to plead guilty and pay more than $430 million to settle charges it had illegally marketed the epilepsy drug Neurontin for unapproved uses. Now, a study in the Journal of Clinical Psychiatry questions whether the lawsuit ended up fueling spending on other epilepsy drugs instead of curbing so-called off-label prescribing (Joelving, 10/26).
This is part of Kaiser Health News' Daily Report - a summary of health policy coverage from more than 300 news organizations. The full summary of the day's news can be found here and you can sign up for e-mail subscriptions to the Daily Report here. In addition, our staff of reporters and correspondents file original stories each day, which you can find on our home page.